CSF samples from 13 probable AD subjects, characterized for T-tau, P-tau and Aβ42 levels determined by ELISA kits (Innogenetics, Figure 3A), and 13 non-disease controls (NDC) were evaluated. Here, MAPT is linked to Alzheimer disease.